STRO.NASDAQSutro Biopharma, INC

Form 4: Sutro Biopharma COO Jane Chung Reports Stock Transactions

Sentiment:

SEC Form 4 Filing

📋All filings for Sutro Biopharma, INC
🔒Login to Follow

Jane Chung, COO of Sutro Biopharma, reports the vesting of restricted stock units and associated tax withholding.

Summary

  • On March 4, 2025, Jane Chung, the President and COO of Sutro Biopharma, engaged in transactions involving the company's common stock and restricted stock units (RSUs).
  • Ms. Chung vested 7,875 RSUs, which converted into common stock.
  • 2,334 shares were withheld by Sutro Biopharma to cover income tax obligations related to the RSU settlement at a price of $1.42 per share.
  • Following these transactions, Ms. Chung directly owns 98,308 shares of Sutro Biopharma common stock and 7,875 RSUs.

Sentiment

Score: 5

Explanation: This is a routine regulatory filing related to executive compensation, and does not contain information that would significantly impact investor sentiment.

Industry Context

This is a standard Form 4 filing, which is common for corporate insiders who have transactions in their company's stock. It reflects part of the executive compensation package.

Stakeholder Impact

  • The transactions have a minor impact on shareholders as they relate to executive compensation and do not represent a significant change in the company's financial position.

Key Dates

DateDescription
03/04/2023RSUs vest as to 1/4th of the total award annually beginning on this date.
03/04/2025Date of the reported transactions: vesting of RSUs and tax withholding.
03/04/2026Expiration date of the Restricted Stock Units.
03/06/2025Date of signature on the Form 4 filing.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.